Who Paid My Doc
Kevin Tse
Allergy & Immunology La Jolla, CA Medical Doctor
NPI 1558528976 CMS profile 1176119
9350 Campus Point Dr, Suite 2-C, La Jolla, CA 92037
General payments
$352
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Kevin Tse of La Jolla, CA is reported in the CMS Open Payments database as having received $352 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 24th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $122 | 1 | |
| 2022 | General | $175 | 1 | |
| 2019 | General | $55 | 1 |
Beside peers
- Kevin Tse
- Allergy & Immunology median
- Middle half of Allergy & Immunology
- National median
In program year 2025, general payments to Kevin Tse were reported at $0. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.
Show as a table
| Year | Kevin Tse | Allergy & Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $55 | $378 | $115–$1,178 | $163 |
| 2020 | $0 | $303 | $75–$1,581 | $114 |
| 2021 | $0 | $407 | $122–$1,475 | $132 |
| 2022 | $175 | $357 | $120–$1,340 | $149 |
| 2023 | $122 | $445 | $124–$1,536 | $160 |
| 2024 | $0 | $541 | $129–$1,763 | $164 |
| 2025 | $0 | $682 | $143–$2,317 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 29 drugsPart D claims
2,441
Drug cost
$2,044,559
Branded share of claims
46.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dupixent Pen Dupilumab | Brand | 179 | $647,403 | |
| Orladeyo Berotralstat Hydrochloride | Brand | 13 | $544,409 | |
| Xolair Omalizumab | Brand | 67 | $308,696 | |
| Breyna Budesonide/Formoterol Fumarate | Brand | 205 | $104,288 | |
| Fasenra Pen Benralizumab | Brand | 17 | $91,462 | |
| Dupixent Syringe Dupilumab | Brand | 25 | $89,584 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 172 | $87,249 | |
| Dulera Mometasone/Formoterol | Brand | 27 | $36,118 | |
| Xhance Fluticasone Propionate | Brand | 15 | $27,594 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 13 | $19,124 |
The 10 drugs with the highest cost, of 29 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy & Immunology in California
Tyler Basen
Allergy & Immunology · Mission Viejo, CA
Geoffrey Carlson
Allergy & Immunology · Travis Afb, CA
Amit Patel
Allergy & Immunology · Upland, CA
Rebecca Chinthrajeh
Allergy & Immunology · Palo Alto, CA
Imran Junaid
Allergy & Immunology · Concord, CA
Sheila Bonilla-Tandoc
Allergy & Immunology · Los Angeles, CA
Related records
Allergy & Immunology in California
Practitioners in the same specialty and state, ranked by reported value.
All Allergy & Immunology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.